Stock Price & Analysis

Based on the provided data and current market conditions, here's a comprehensive analysis of OGN stock:

Technical Analysis

The stock is showing signs of recovery after a recent decline:

• Current price: $16.15 (as of Feb 25, 2025)
• Notable price movement: +6.96% in regular trading hours
• Trading volume: 4.44M shares, indicating strong market interest
• RSI-14: 56.04, suggesting neutral momentum
• MACD: Slightly positive with 0.02, showing potential upward momentum

Fundamental Analysis

Key financial metrics:

• Revenue growth: +1.44% YoY ($6.26B in 2023)
• Net income: $1.02B in 2023, up from $917M in 2022
• EPS: $3.99 (2023), improved from $3.59 (2022)
• Current ratio: 1.54, indicating healthy liquidity
• Net margin: 16.33%, showing strong profitability

Recent Developments

According to recent reports, Organon has made significant progress:

• FDA approval for VTAMA cream for atopic dermatitis treatment
• Strong cash flow generation (~$700M as of November)
• Maintained quarterly dividend of $0.28 per share
• Nexplanon expected to reach $1B in revenue by 2025

Buy/Sell Recommendation

SELL for the following reasons:

1. Despite recent positive price movement, the stock remains below key moving averages
2. Technical indicators suggest potential resistance ahead
3. While fundamentals are solid, the company faces industry-wide funding challenges
4. Recent analyst downgrades to Hold status

Based on the provided data and market analysis, here's the price prediction for OGN stock in 2025:

Technical Analysis

The stock has shown significant volatility in recent months, with a clear downward trend from $22.35 in August 2024 to current levels around $16.15. However, recent price action shows signs of potential reversal.

Fundamental Drivers

According to recent analyst reports, OGN has several positive catalysts for 2025:

• Nexplanon, the company's largest product, is expected to reach $1 billion in sales by 2025
• The October 2024 acquisition of Dermavant Sciences Ltd. and FDA approval of VTAMA cream opens new growth opportunities
• Strong free cash flow generation target of ~$1 billion for 2025
• Currently trading at an attractive forward P/E of 3.7x, well below industry average of 17.62x

Price Target Analysis

Wall Street analysts have set a consensus price target implying 36.13% upside potential. This target is supported by:

• Expanding product portfolio in women's health
• Cost control initiatives
• Stable dividend payments ($0.28 quarterly)
• Strong cash flow generation

2025 Price Prediction

Based on technical and fundamental analysis, OGN stock is expected to reach $20-22 range by end of 2025, representing approximately 25-35% upside from current levels. The primary drivers will be successful execution of growth initiatives and potential multiple expansion as the market recognizes the company's improving fundamentals.

The S1 support level for OGN Stock is $14.81 ,The R1 resistant level for OGN Stock is $16.76.

As of the end of day on 2025-02-26, the price of OGN Stock was $16.

The target price for OGN Stock according to analyst rating is 19.60, with the highest price target at 26.00 and the lowest at 16.00. Analysts have a Hold rating on OGN Stock overall.

The market cap of OGN is $4.2B.

Based on the current market data, OGN appears to be trading at a relatively low price of $0.0726, showing a modest regular market percentage change of 1.823%. The stock's trading range for the day has been between $0.0671 and $0.0731, with significant volume of 22.8M shares. The current price level and trading patterns suggest OGN is not overvalued at these levels. Technical analysis indicates the stock is trading near its recent support levels, and the volume spike suggests increased market interest. The price-to-earnings and other valuation metrics are favorable compared to industry peers at these price levels. Market sentiment appears neutral to slightly positive based on today's trading activity.

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Based on the provided data and technical analysis, here's the 2030 price prediction for OGN stock:

OGN stock is projected to reach $28-32 by 2030, representing a potential upside of approximately 75-100% from current levels ($16.13), driven by the company's steady fundamentals in women's health segment and strategic expansion in biosimilars market.

The stock's current technical indicators and analyst consensus suggest a stable growth trajectory, with support at $14.81 and resistance at $16.76, indicating a strong base for long-term appreciation.

Recent institutional backing, particularly Barclays' $24 price target and positive outlook on fundamentals, reinforces the stock's potential for sustained growth through 2030.

OGN has a total of 10000 employees.